TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04654767

Intervention type: OTHER
Intervention: Tissue sampling
Description: Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.

Intervention type: OTHER
Intervention: Tissue sampling
Description: Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.

Intervention type: OTHER
Intervention: Tissue sampling
Description: Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.
Study: NCT05657418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS107
Description: JS107, i.v., q3w

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS107 combination with Toripalimab
Description: JS107 i.v., q3w combine with Toripalimab
Study: NCT05780034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC676
Description: AC676 will be given orally (PO) on a 28-day cycle.
Study: NCT05316792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: 30 min walking on the treadmill and tartan floor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: 30 min walking on the treadmill and tartan floor
Study: NCT06376877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
Study: NCT05664789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N acetyl cysteine
Description: N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT05964920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Two placebo injections one at baseline and one week 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline + Resistance exercise training
Description: Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate + Resistance exercise training
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
Study: NCT05607121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: transcranial magnetic stimulation
Study: NCT05614401

Intervention type: OTHER
Intervention: functional and medical information
Description: 1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.

Intervention type: OTHER
Intervention: functional and medical information
Description: 1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
Study: NCT04664907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videomusic listening
Description: Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
Study: NCT06272149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R08b
Description: VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
Study: NCT06405802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-evaluation
Description: Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-evaluation
Description: Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
Study: NCT06380933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
Study: NCT05904132

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tACS device
Description: you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS device
Description: you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
Study: NCT05989971

Intervention type: OTHER
Intervention: continuous renal replacement therapy
Description: continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
Study: NCT06344689

Intervention type: OTHER
Intervention: Surgical treatment
Description: Patients underwent surgical treatment of ectropion were included in this study.
Study: NCT05762562

Intervention type: OTHER
Intervention: Telerehabilitation with open source platforms
Description: Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program.
Study: NCT05300659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action for Rehabilitation for Neurological Injury (ARNI)
Description: If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
Study: NCT05327088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
Study: NCT05961540

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: 1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding behavioural intervention for mothers of infants with CHD
Description: Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD.
Study: NCT04887506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVT-45
Description: 250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytiga
Description: 500 mg tablet, two tablets administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
Study: NCT05440747

Intervention type: OTHER
Intervention: TFR(Treatment-Free Remission)
Description: Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
Study: NCT05891717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Twice per week for 8 weeks. Total 16 sessions will given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Twice per week for 8 weeks. Total 16 sessions will given.
Study: NCT04975503

Intervention type: OTHER
Intervention: Observing cardiovascular risk factors
Description: Documenting the presence or absence of CVD risk factors in each participant.

Intervention type: OTHER
Intervention: Observing cardiovascular risk factors
Description: Documenting the presence or absence of CVD risk factors in each participant.
Study: NCT03531476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Chronic Pain Management Program
Description: With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
Study: NCT06274606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
Study: NCT06442124

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography (EMG)
Description: The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography (EMG)
Description: The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction
Study: NCT04878549

Intervention type: DIAGNOSTIC_TEST
Intervention: 5-gene transcription signature
Description: This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.

Intervention type: DIAGNOSTIC_TEST
Intervention: 5-gene transcription signature
Description: This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.

Intervention type: DIAGNOSTIC_TEST
Intervention: 5-gene transcription signature
Description: This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
Study: NCT06432673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral solution
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral solution
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral capsule
Description: Oral capsule
Study: NCT05321199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
Study: NCT04618367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously every 3weeks
Study: NCT05473611

Intervention type: PROCEDURE
Intervention: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Description: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring

Intervention type: PROCEDURE
Intervention: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Description: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring

Intervention type: PROCEDURE
Intervention: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Description: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Study: NCT06189378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion of patient-provided pictures into blood pressure diaries
Description: Patient-provided pictures with positive meaning were included into blood pressure diaries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional blood pressure diary
Description: Conventional blood pressure diary
Study: NCT05415566

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: toy nebulizer and toy mask
Description: The treatment was administered using therapeutic play.
Study: NCT06131021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
Study: NCT05289765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A natural neutral Ecological Extra Virgin Olive Oil based gel
Description: A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products
Description: A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
Study: NCT06320132

Intervention type: OTHER
Intervention: Treatment of spontaneous intracranial hemorrhage
Description: Data collection of therapeutic approach, including radiological, medical, surgical therapies.

Intervention type: OTHER
Intervention: Treatment of spontaneous intracranial hemorrhage
Description: Data collection of therapeutic approach, including radiological, medical, surgical therapies.
Study: NCT05524662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
Study: NCT05827094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
Study: NCT06479928

Intervention type: OTHER
Intervention: delivery mode
Description: Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.

Intervention type: OTHER
Intervention: delivery mode
Description: Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.
Study: NCT06384105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: frames per second
Description: Other settings for frames per second

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: frames per second
Description: Other settings for frames per second